Yahoo Web Search

Search results

1. sciencebasedmedicine.org › a-critical-look-at-theConclusions Not So NICE: A Critical Analysis of the NICE ...

   sciencebasedmedicine.org › a-critical-look-at-the

   • Cached

   Oct 17, 2021 · The NICE Review of gonadotropin-releasing hormone analogues (GnRHa), medications that block the production of the sex hormones testosterone and estrogen and are used to treat gender dysphoria in adolescents, was published in March 2021. The review included nine observational studies published no later than October 14, 2020: five retrospective studies, three prospective longitudinal studies ...

   • United Kingdom

     Science-Based Medicine. Exploring issues and controversies...

   • Ideology, Not Science

     Dr. Gorski's full information can be found here, along with...

2. segm.org › NICE_gender_medicine_systematic_reviewNew Systematic Reviews of Puberty Blockers and Cross-Sex ...

   segm.org › NICE_gender_medicine_systematic_review

   • Cached

   Mar 31, 2021 · The reviews were published in March 2021. The review of GnRH agonists (puberty blockers) makes for sobering reading. Its major finding is that GnRH agonists lead to little or no change in gender dysphoria, mental health, body image and psychosocial functioning. In the few studies that did report change, the results could be attributable to bias ...

3. transfemscience.org › articles › puberty-blockersPuberty Blockers: A Review of GnRH Analogues in Transgender ...

   transfemscience.org › articles › puberty-blockers

   Jan 30, 2022 · This included patients who received puberty suppression, hormone therapy, and/or surgery. Notably, 5 of them regretted their treatment because of a lack of social acceptance (Wiepjes et al., 2018). De Vries et al. (2014), found none of the 55 transgender patients they followed regretted receiving puberty blockers, hormone therapy, or surgery ...

4. pmc.ncbi.nlm.nih.gov › articles › PMC9939757Luteinizing hormone-releasing hormone agonists versus ...

   pmc.ncbi.nlm.nih.gov › articles › PMC9939757

   Moreau JP, Delavault P, Blumberg J. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. Clin Ther (2006) 28(10):1485–508. doi: 10.1016/j.clinthera.2006.10.018 [ DOI ] [ PubMed ] [ Google Scholar ]

5. www.nature.com › articles › s41523/023/00523-4An emerging generation of endocrine therapies in breast ...

   www.nature.com › articles › s41523/023/00523-4

   Apr 5, 2023 · Anti-estrogen therapy is a key component of the treatment of both early and advanced-stage hormone receptor (HR)-positive breast cancer. This review discusses the recent emergence of several anti ...

6. acsjournals.onlinelibrary.wiley.com › doi › 10Does hormone therapy impact cognition in patients with ...

   acsjournals.onlinelibrary.wiley.com › doi › 10

   Feb 2, 2024 · INTRODUCTION. Hormone therapy (HT) is a standard-of-care option for prostate cancer (PC). In hormone-sensitive disease, androgen-deprivation therapy (ADT) consists in reducing gonadal production of testosterone by using agonists or antagonists of luteinizing hormone-releasing hormone and preventing the binding of testosterone to androgen receptor in the tumoral cells by using antiandrogens.

7. People also ask

   Can hormone treatment change a'regression-to-the-mean' score?

   • The reviewers noted that “a fundamental limitation of all the uncontrolled studies in this review is that any changes in scores from baseline to follow-up could be attributed to a regression-to-the-mean,” rather than the beneficial effects of hormone treatment.

   New Systematic Reviews of Puberty Blockers and Cross-Sex Hormones

   segm.org/NICE_gender_medicine_systematic_review_finds_poor_quality_evidence

   See all results for this question

   What are the side effects of cyclical hormone replacement therapy (HRT)?

   • Progestogenic side effects - tend to occur in a cyclical pattern during the progestogen phase of cyclical hormone replacement therapy (HRT). Change progestogen type from a more androgenic one (such as norethisterone and norgestrel) to a less androgenic one (such as medroxyprogesterone or dydrogesterone).

   Hormone Replacement Therapy (HRT) Guidance and Treatment Pathway

   swlimo.southwestlondon.icb.nhs.uk/wp-content/uploads/2021/06/Hormone-Replacement-Therapy-HRT-Guidance-and-Treatment-Pathway.pdf

   See all results for this question

   When should hormone treatment be started?

   • Hormonal treatment should be started and continued until at least the age of natural menopause (51 years). The baseline population risk of diseases such as breast cancer and cardiovascular disease increases with age and is very low in women aged under 40.

   Hormone Replacement Therapy (HRT) Guidance and Treatment Pathway

   swlimo.southwestlondon.icb.nhs.uk/wp-content/uploads/2021/06/Hormone-Replacement-Therapy-HRT-Guidance-and-Treatment-Pathway.pdf

   See all results for this question

   How long should HRT be continued?

   • HRT should be continued for as long as it is of benefit, and improvement in quality of life outweighs risks. Offer gradual reduction of HRT to limit recurrence of symptoms in the short term (gradually reducing or immediately stopping HRT makes no difference to their symptoms in the longer term).

   Hormone Replacement Therapy (HRT) Guidance and Treatment Pathway

   swlimo.southwestlondon.icb.nhs.uk/wp-content/uploads/2021/06/Hormone-Replacement-Therapy-HRT-Guidance-and-Treatment-Pathway.pdf

   See all results for this question

   Does gonadotropin-releasing hormone analog treatment affect reproductive axis?

   • Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. The Journal of Clinical Endocrinology and Metabolism, 84 (1), 44–49.

   Puberty Blockers: A Review of GnRH Analogues in Transgender Youth

   transfemscience.org/articles/puberty-blockers/

   See all results for this question

   Is there a roadblock to gender-affirming care?

   • The NICE review of puberty blockers has been favorably commented on by the Society for Evidence-Based Gender Medicine (SEGM), who have used it to argue against gender-affirming care. Opponents to gender-affirming care, such as Stephen B. Levine, have also cited this source.

   conclusions not so nice: a critical analysis of the nice evidence

   sciencebasedmedicine.org/a-critical-look-at-the-nice-review/

   See all results for this question

8. swlimo.southwestlondon.icb.nhs.uk › wp-contentHormone Replacement Therapy (HRT) Guidance and Treatment Pathway

   swlimo.southwestlondon.icb.nhs.uk › wp-content

   Hormone Replacement Therapy (HRT) Guidance and Treatment Pathway Lead author: Priya Patel, Appendix update by Merton & Wandsworth CCG Medicines Optimisation Team Approved by: Croydon Prescribing Committee November 2018, updated January 2020 Review: January 2021 Route of administration1